

Michael J. Silver

Partner

New York

Baltimore

Biography

Michael Silver is among the firm's most experienced and accomplished corporate lawyers. In over 40 years of practice, Michael has handled everything from initial public offerings (IPOs) to large-scale public mergers and acquisitions (M&A) for clients in many industries.

Currently Michael advises on M&A, capital markets, and corporate governance for clients in the life sciences; manufacturing; technology, media, and telecommunications (TMT); and business services areas, but he has extensive experience in the insurance industry as well. He has adapted his skills and approach to practice as the legal landscape has evolved, while maintaining a consistent focus on outstanding and timely client service.

Michael is also a leader in the firm. He was elected in consecutive terms on the Global Board of Hogan Lovells, and for many years he led its New York Corporate Practice Group.

Michael has been consistently ranked in the highest tiers of corporate lawyers in every year of publication of *Chambers'* guides to U.S. lawyers, and in other major legal directories.

Representative experience

Public acquisition of Cyan, Inc. by Ciena Corporation for cash and stock in 2015, valued at over US\$300m.

Public acquisition of Covance Corporation by LabCorp



Phone

+1 212 918 8235 (New York)

+1 410 659 2741 (Baltimore)

Fax

+1 212 918 3100 (New York)

+1 410 659 2701 (Baltimore)

Email

michael.silver@hoganlovells.com

Practices

Capital Markets

Mergers and Acquisitions

Private Equity

Corporate Governance

Securities and Public Company
Advisory

Industries

Insurance

Life Sciences and Health Care

Technology and Telecoms

Diversified Industrials

for cash and stock in 2015 valued at US\$6bn, and related debt financing transactions.

Acquisition of Parsons Brinkerhoff by WSP Global in 2014 for over US\$1bn in cash.

Public sale of Martek Biosciences Corporation to Royal DSM.

Take Private sale of American Commercial Lines to Platinum Equity.

Acquisition of Walker Industries by Wabash National Corporation.

Over US\$4bn in senior notes offerings for LabCorp.

IPO of Colfax Corporation.

Awards and rankings

- Capital Markets: Equity, Notable Practitioner, *IFLR1000*, 2020
- M&A, Notable Practitioner, *IFLR1000*, 2020
- Private Equity, Notable Practitioner, *IFLR1000*, 2020
- BTI Client Service All-Star, *BTI Consulting Group*, 2016-2017
- Acritas Star: M&A, Regulatory, *Acritas Stars Independently Rated Lawyers*, 2017-2020
- Baltimore Securities / Capital Markets Law "Lawyer of the Year", *Best Lawyers*, 2017
- Corporate Law, *The Best Lawyers in America*, 2005-2019
- Securities / Capital Markets Law, *The Best Lawyers in America*, 2005-2019
- Corporate/M&A (Maryland), *Chambers USA*, 2004-2021
- Global M&A Lawyer of the Year, 2014
- Winner of ILO Client Choice Award for Maryland - General Corporate, *ILO Client Choice Guide*, 2014
- Finance: Capital Markets: Equity Offerings, *Legal 500 US*, 2014
- Maryland Super Lawyers, 2007-2013

Areas of focus

Raising Equity Capital
Initial Public Offerings
Emerging Companies
Disclosure and Reporting Obligations
Public Company Mergers and Acquisitions
Cross-border Mergers and Acquisitions
Carve-outs, Spin-offs, and Split-offs
Hostile Takeovers and Takeover Defense
Special Committee and Independent Director Representations

Education and admissions

Education

J.D., The University of Chicago Law School, 1980

A.B., Harvard University, magna cum laude, 1977

Bar admissions and qualifications

New York

Maryland

District of Columbia

- Mergers, Acquisitions and Buyouts, *Legal 500 US*, 2012-2013

Latest thinking and events

- News
 - SEC staff issues sample comments regarding climate change disclosure
- News
 - SEC approves Nasdaq's board diversity rules
- Press Releases
 - Hogan Lovells advises LabCorp in US\$1 billion senior notes offering
- Press Releases
 - Hogan Lovells advises Labcorp on US\$150m acquisition of Myriad Genetics' Vectra testing business
- News
 - SEC alleges Reg FD violation for selective disclosure to analysts aimed at reducing consensus revenue estimate
- News
 - SEC updates MD&A and other financial disclosure requirements